Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. Context Current approaches to optimise antibodies, even those that use machine learning, still… Read More
Exscientia has announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, UK, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology. In parallel, Exscientia is building a new 26,000 square… Read More
Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR: How AI has been used in this process and what benefits has… Read More
Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More
